Vilanterol

A long-acting beta agonist used in the treatment of respiratory diseases

Vilanterol

Chemical structure of Vilanterol

Vilanterol is a long-acting beta agonist (LABA) used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is often combined with other medications, such as inhaled corticosteroids or anticholinergics, to enhance its therapeutic effects.

Pharmacology

Vilanterol works by stimulating beta-2 adrenergic receptors in the bronchioles, leading to bronchodilation and improved airflow in patients with obstructive airway diseases. As a LABA, it provides prolonged bronchodilation, making it suitable for once-daily dosing.

Mechanism of Action

Vilanterol binds to beta-2 adrenergic receptors on the smooth muscle cells of the airways. This binding activates adenylate cyclase, increasing the levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels lead to the relaxation of bronchial smooth muscle, resulting in bronchodilation.

Clinical Use

Vilanterol is primarily used in combination with other agents for the treatment of asthma and COPD. It is not recommended for use as a monotherapy due to the risk of asthma-related death associated with LABAs when used alone.

Combination Products

Vilanterol is available in combination with:

• Fluticasone furoate, an inhaled corticosteroid, marketed under the brand name Breo Ellipta.
• Umeclidinium, an anticholinergic, marketed under the brand name Anoro Ellipta.

Side Effects

Common side effects of vilanterol include headache, throat irritation, and cough. Serious side effects may include paradoxical bronchospasm, tachycardia, and hypokalemia.

Contraindications

Vilanterol is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It should be used with caution in patients with cardiovascular disorders, thyrotoxicosis, or diabetes mellitus.

Related pages

• Asthma
• Chronic obstructive pulmonary disease
• Beta-2 adrenergic receptor
• Inhaled corticosteroid